SIIT

What SIIT does

S.I.I.T. S.r.l. is an Italian contract developer and manufacturer (CDMO) of food supplements, medical devices, and over-the-counter (OTC) pharmaceutical products, founded in 1959 and headquartered in Trezzano sul Naviglio (Milan). The company provides end-to-end services — from product conception to regulatory support — in both solid and liquid dosage forms, serving pharmaceutical and nutraceutical companies globally. The business operates two revenue streams: contract development and manufacturing for trade and industry partners, and a licensing-out division that offers a complete pipeline of ready-to-market products to customers worldwide.

The technology foundation is built on 26+ proprietary drug-delivery platforms designed to enhance bioavailability, absorption, and consumer compliance. Headline technologies include 3W Technology (a patented multilayer tablet system with staged release at 5 minutes, 45 minutes, and 8 hours), HP-LYPOSOME (liposomal encapsulation for liquid forms), LYPO-SOLID (liposomal solid delivery), MICROPUFF (sublingual spray delivery), DUOCAM (dual-chamber sachets isolating reactive ingredients), SMATAB (crunchable mini-tablets in stick packs), MICROCOAT (probiotic stability coating), UTD-3-PHASE (twist-cap live probiotic delivery), and ICE VITA POP (frozen popsicle delivery). The company holds granted European patents including EP2942050 (IMBRESOL vitamin D sublingual spray), EP3184115 (tamarind extract composition for reflux), and EP3023093 (diosmectite composition), with flagship technologies protected as internationally registered trademarks.

SIIT monetizes through two complementary models: professional services revenue from contract manufacturing and licensing/royalties income from out-licensing its 50+ ready-to-market products spanning gastrointestinal care, women's health, sleep, immunity, energy, beauty, joint care, metabolic health, weight management, and pediatric categories. Customer acquisition is anchored in international trade shows — CPHI Worldwide (Milan, Barcelona, Frankfurt, North America), Vitafoods Europe, SupplySide West, and PLMA Amsterdam — supplemented by direct B2B sales. The customer base exceeds 1,200 references across 70-75+ countries, depending on source. The company operates seven facilities in the Milan area covering solid manufacturing, solid packaging, liquid manufacturing, low-water-activity production, logistics, and an internal quality control laboratory.

Name

SIIT

Legal name

S.I.I.T. S.r.l.

Website

https://siitgroup.com

Company type

Private

Founded year

1959

Operating status

Operating

Headcount range

251–500 employees

Short description

S.I.I.T. S.r.l. is an Italian contract developer and manufacturer (CDMO) of food supplements, medical devices, and OTC products serving pharmaceutical and nutraceutical companies worldwide across 70+ countries, via proprietary manufacturing and licensing out of ready-to-market products.

Ownership category

akta.pro rank

Product category

Contract Development & Manufacturing (CDMO) for Healthcare Products

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

akta.pro secondary industry

Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Contract development manufacturing
• Food supplement manufacturing
• Medical device manufacturing
• Drug delivery technology
• Nutraceutical CDMO

Headquarters

HQ city

Trezzano Sul Naviglio

HQ country

Italy

HQ region

Europe

Offices7 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Contract Development & Manufacturing: S.I.I.T. operates as an Italian Innovative Healthcare Products Contract Developer & Manufacturer (CDMO) providing holistic services from product conception to regulatory services for Food Supplements, Medical Devices, and OTC in solid and liquid dosage forms since 1959.
2. Licensing Out: The company licenses out a complete pipeline of Innovative Healthcare Products ready for market in various therapeutic areas and dosage forms. Strong know-how and continuous investment in clinical and technological research drives commercial success.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

S.I.I.T. S.r.l. is an Italian Contract Developer & Manufacturer (CDMO) that designs, develops, and manufactures Food Supplements, Medical Devices, and OTC products in solid and liquid dosage forms for pharmaceutical and nutraceutical customers. The company also operates a Licensing Out Division that licenses a complete pipeline of 50+ ready-to-market innovative healthcare products covering indications from gastrointestinal care to beauty, supported by 26+ proprietary drug delivery technologies (3W Technology, HP-LYPOSOME, MICROPUFF, DUOCAM, FIZZY BALLS, SMATAB, UTD-3-PHASE, MICROIL, etc.). Services span from product conception through regulatory support, leveraging integrated solid and liquid manufacturing plants, a Low Water Activity plant, and an internal Quality Control Laboratory in Trezzano sul Naviglio (Milan).

Product overview

SIIT (S.I.I.T.) is an Italian Innovative Healthcare Products Contract Developer & Manufacturer offering a comprehensive portfolio of Food Supplements, Medical Devices, and OTC products in solid and liquid dosage forms. The company's product portfolio includes: DURAVIT line products (DURAVIT IMMUNITY, DURAVIT ENERGY, DURAVIT MULTIVIT, DURAVIT SLEEP, DURAVIT SLEEP & RELAX, DURAVIT BEAUTY, DURAVIT IRON, DURAVIT WOMAN 50+, DURAVIT PREGNANCY, DURAVIT MAN 50+), NUTRA FIZZIES effervescent tablets (NUTRA FIZZIES IMMUNITY, NUTRA FIZZIES ENERGY, NUTRA FIZZIES MULTIVIT, NUTRA FIZZIES BEAUTY, NUTRA FIZZIES DIGESTION), Lypochrono/LypoMelatonin sublingual sprays and sticks for sleep support, NutriPOCKET stick packs (NutriPOCKET Vitamin D3, NutriPOCKET Multivitamin, NutriPOCKET Multivitamin KIDS, NutriPOCKET Iron), MY SQUEEZE squeeze bottles for liquid delivery, CAPTOSIDER iron deficiency products, Medical devices including CAPTOGASTRIL, CAPTOMUCIL nasal sprays, and TAMARACID PLUS, and specialty products like SIMESTER, fertiFEM, fertiMAX, WELLMAMA, BIO-C, ARTHOS, KEFBONES, YOUTIN, REBOOT, and ICE frozen supplements. These products cover therapeutic areas including gastrointestinal care, women's health, sleep & relax, multivitamin/energy/immune support, cough & cold, baby care, beauty & skin, muscles/bones/joint care, supportive care, and men's health. The company develops innovative drug delivery technologies including 3W Technology (multilayer tablets), HP-LYPOSOME, LYPO-SOLID, MICROPUFF, DUOCAM, FIZZY BALLS, SMATAB, UTD-3-PHASE, MY SQUEEZE, ICE VITA POP, and MICROIL that enhance bioavailability and absorption of active ingredients.

Differentiator

Problem solved

Functional benefit

Products and services

• Contract Development & Manufacturing (CDMO) Services
• Licensing Out of Ready-to-Market Innovative Healthcare Products

Segments2 records

Ideal customer profiles2 records

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature26 records

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Aenova Holding: German-headquartered CDMO offering contract manufacturing for pharmaceuticals, food supplements, and consumer health products across solid, semi-solid, and liquid dosage forms. Directly comparable to SIIT as a European B2B supplement CDMO with multiple manufacturing sites and global reach.
• Catalent: Global CDMO leader providing contract development and manufacturing for pharmaceuticals and consumer health products including softgel, oral, and specialty delivery formats. Comparable to SIIT in OTC/supplement CDMO scope, though at significantly greater scale.
• Recipharm: European CDMO with broad solid dose, semi-solid, and biologics manufacturing across multiple sites. Comparable to SIIT in B2B contract pharma/manufacturing for finished dosage forms targeted at similar customers.
• Dompé Farmaceutici: Italian pharmaceutical company with significant consumer health and OTC manufacturing capability. Comparable to SIIT as a domestic Italian player in pharmaceutical/consumer healthcare products with manufacturing operations.

Direct peers

• Labomar: Italian CDMO specializing in contract development and manufacturing of food supplements, medical devices, and cosmetics in multiple dosage forms (liquids, tablets, sachets). Highly comparable to SIIT as a mid-sized Italian nutraceutical CDMO with own-brand and licensing activities.
• Sirio Pharma: Chinese-headquartered global CDMO focused on nutraceutical, health, and personal care products across gummies, softgels, oral liquids, and other consumer health formats. Directly comparable to SIIT in CDMO services, delivery technology breadth, and international customer base.
• HERMES Arzneimittel: German CDMO specializing in consumer health/OTC products, food supplements, and effervescent tablets. Directly comparable to SIIT in dosage-form innovation (effervescent/orodispersible) and European B2B supplements market focus.

Others

• Eurofins Scientific: Global testing and contract laboratory services provider with extensive CDMO-adjacent capabilities including pharmaceutical and nutraceutical testing. Comparable to SIIT in serving regulated consumer health customers, though primarily in QC/testing rather than manufacturing.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/siitgroup

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SIIT